Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fate Therapeutics (FATE) Revenue (2016 - 2025)

Fate Therapeutics' Revenue history spans 14 years, with the latest figure at $1.4 million for Q4 2025.

  • For Q4 2025, Revenue fell 26.4% year-over-year to $1.4 million; the TTM value through Dec 2025 reached $6.6 million, down 51.24%, while the annual FY2025 figure was $6.6 million, 51.24% down from the prior year.
  • Revenue reached $1.4 million in Q4 2025 per FATE's latest filing, down from $1.7 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $59.0 million in Q1 2023 to a low of $933000.0 in Q2 2023.
  • Average Revenue over 5 years is $11.8 million, with a median of $4.9 million recorded in 2024.
  • The largest YoY upside for Revenue was 625.83% in 2024 against a maximum downside of 96.74% in 2024.
  • A 5-year view of Revenue shows it stood at $17.1 million in 2021, then soared by 159.86% to $44.4 million in 2022, then crashed by 96.22% to $1.7 million in 2023, then rose by 10.98% to $1.9 million in 2024, then dropped by 26.4% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for FATE's Revenue are $1.4 million (Q4 2025), $1.7 million (Q3 2025), and $1.9 million (Q2 2025).